Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Price A

Showing results (11-20 of 11) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 11 results.
The Lancet. Oncology|July 5, 2025
First-in-human results of terbium-161 [<sup>161</sup>Tb]Tb-PSMA-I&T dual beta-Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 studyJames P Buteau, Louise Kostos, Price A Jackson, et al.
Pageof 2

Showing results (11-20 of 11) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 11 results.
The Lancet. Oncology|July 5, 2025
First-in-human results of terbium-161 [<sup>161</sup>Tb]Tb-PSMA-I&T dual beta-Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 studyJames P Buteau, Louise Kostos, Price A Jackson, et al.
Pageof 2